1. Home
  2. BBIO vs KVYO Comparison

BBIO vs KVYO Comparison

Compare BBIO & KVYO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BBIO
  • KVYO
  • Stock Information
  • Founded
  • BBIO 2015
  • KVYO 2012
  • Country
  • BBIO United States
  • KVYO United States
  • Employees
  • BBIO N/A
  • KVYO N/A
  • Industry
  • BBIO Biotechnology: Pharmaceutical Preparations
  • KVYO
  • Sector
  • BBIO Health Care
  • KVYO
  • Exchange
  • BBIO Nasdaq
  • KVYO Nasdaq
  • Market Cap
  • BBIO 9.4B
  • KVYO 9.5B
  • IPO Year
  • BBIO 2019
  • KVYO 2023
  • Fundamental
  • Price
  • BBIO $55.32
  • KVYO $26.14
  • Analyst Decision
  • BBIO Strong Buy
  • KVYO Strong Buy
  • Analyst Count
  • BBIO 16
  • KVYO 23
  • Target Price
  • BBIO $64.44
  • KVYO $44.00
  • AVG Volume (30 Days)
  • BBIO 2.0M
  • KVYO 4.0M
  • Earning Date
  • BBIO 11-11-2025
  • KVYO 11-05-2025
  • Dividend Yield
  • BBIO N/A
  • KVYO N/A
  • EPS Growth
  • BBIO N/A
  • KVYO N/A
  • EPS
  • BBIO N/A
  • KVYO N/A
  • Revenue
  • BBIO $235,812,000.00
  • KVYO $1,078,202,000.00
  • Revenue This Year
  • BBIO $115.46
  • KVYO $30.57
  • Revenue Next Year
  • BBIO $65.03
  • KVYO $21.32
  • P/E Ratio
  • BBIO N/A
  • KVYO N/A
  • Revenue Growth
  • BBIO 7.62
  • KVYO 33.17
  • 52 Week Low
  • BBIO $21.72
  • KVYO $23.77
  • 52 Week High
  • BBIO $55.32
  • KVYO $49.55
  • Technical
  • Relative Strength Index (RSI)
  • BBIO 59.91
  • KVYO 30.10
  • Support Level
  • BBIO $52.97
  • KVYO $24.93
  • Resistance Level
  • BBIO $55.13
  • KVYO $27.49
  • Average True Range (ATR)
  • BBIO 1.58
  • KVYO 1.63
  • MACD
  • BBIO 0.16
  • KVYO -0.81
  • Stochastic Oscillator
  • BBIO 84.41
  • KVYO 5.67

About BBIO BridgeBio Pharma Inc.

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

About KVYO Klaviyo Inc. Series A

Klaviyo Inc is a technology company that provides a software-as-a-service (SaaS) platform to enable its customers to send the right messages at the right time across email, short message service, and push notifications, more accurately measure and predict performance, and deploy specific actions and campaigns. The platform combines proprietary data and application layers into one solution with machine learning and artificial intelligence capabilities. It is focused on marketing automation within eCommerce as its first application use case. It generates revenue through the sale of subscriptions to its customers for the use of its platform. Geographically, the company generates the majority of its revenue from the Americas, followed by EMEA and APAC.

Share on Social Networks: